These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18579379)

  • 1. Daily salbutamol in young patients with SMA type II.
    Pane M; Staccioli S; Messina S; D'Amico A; Pelliccioni M; Mazzone ES; Cuttini M; Alfieri P; Battini R; Main M; Muntoni F; Bertini E; Villanova M; Mercuri E
    Neuromuscul Disord; 2008 Jul; 18(7):536-40. PubMed ID: 18579379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot trial of albuterol in spinal muscular atrophy.
    Kinali M; Mercuri E; Main M; De Biasia F; Karatza A; Higgins R; Banks LM; Manzur AY; Muntoni F
    Neurology; 2002 Aug; 59(4):609-10. PubMed ID: 12196659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II.
    Frongia AL; Natera-de Benito D; Ortez C; Alarcón M; Borrás A; Medina J; Vigo M; Padrós N; Moya O; Armas J; Carrera-García L; Expósito-Escudero J; Cuadras D; Bernal S; Martorell L; Colomer J; Nascimento A
    Neuromuscul Disord; 2019 Jul; 29(7):517-524. PubMed ID: 31201046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of phenylbutyrate in spinal muscular atrophy.
    Mercuri E; Bertini E; Messina S; Pelliccioni M; D'Amico A; Colitto F; Mirabella M; Tiziano FD; Vitali T; Angelozzi C; Kinali M; Main M; Brahe C
    Neuromuscul Disord; 2004 Feb; 14(2):130-5. PubMed ID: 14733959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Salbutamol on Respiratory Muscle Strength in Spinal Muscular Atrophy.
    Khirani S; Dabaj I; Amaddeo A; Olmo Arroyo J; Ropers J; Tirolien S; Coudert V; Estournet B; Fauroux B; Quijano-Roy S
    Pediatr Neurol; 2017 Aug; 73():78-87.e1. PubMed ID: 28668232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot trial of salbutamol in central core and multi-minicore diseases.
    Messina S; Hartley L; Main M; Kinali M; Jungbluth H; Muntoni F; Mercuri E
    Neuropediatrics; 2004 Oct; 35(5):262-6. PubMed ID: 15534757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol.
    Tiziano FD; Lomastro R; Abiusi E; Pasanisi MB; Di Pietro L; Fiori S; Baranello G; Angelini C; Sorarù G; Gaiani A; Mongini T; Vercelli L; Mercuri E; Vasco G; Pane M; Vita G; Vita G; Messina S; Petillo R; Passamano L; Politano L; Campanella A; Mantegazza R; Morandi L
    J Med Genet; 2019 May; 56(5):293-300. PubMed ID: 30593463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen.
    Coratti G; Pane M; Lucibello S; Pera MC; Pasternak A; Montes J; Sansone VA; Duong T; Dunaway Young S; Messina S; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Tacchetti P; Carnicella S; Sframeli M; Antonaci L; Frongia AL; De Vivo DC; Darras BT; Day J; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Neuromuscul Disord; 2021 Jul; 31(7):596-602. PubMed ID: 34099377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
    Kirschner J; Schorling D; Hauschke D; Rensing-Zimmermann C; Wein U; Grieben U; Schottmann G; Schara U; Konrad K; Müller-Felber W; Thiele S; Wilichowski E; Hobbiebrunken E; Stettner GM; Korinthenberg R
    Neuromuscul Disord; 2014 Feb; 24(2):134-42. PubMed ID: 24300782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.
    Ramsey D; Scoto M; Mayhew A; Main M; Mazzone ES; Montes J; de Sanctis R; Dunaway Young S; Salazar R; Glanzman AM; Pasternak A; Quigley J; Mirek E; Duong T; Gee R; Civitello M; Tennekoon G; Pane M; Pera MC; Bushby K; Day J; Darras BT; De Vivo D; Finkel R; Mercuri E; Muntoni F
    PLoS One; 2017; 12(2):e0172346. PubMed ID: 28222119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy.
    Fowler EG; Graves MC; Wetzel GT; Spencer MJ
    Neurology; 2004 Mar; 62(6):1006-8. PubMed ID: 15037714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.
    Kissel JT; McDermott MP; Mendell JR; King WM; Pandya S; Griggs RC; Tawil R;
    Neurology; 2001 Oct; 57(8):1434-40. PubMed ID: 11673585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial.
    Payan CA; Hogrel JY; Hammouda EH; Lacomblez L; Ollivier G; Doppler V; Eymard B; Attarian S; Pouget J; Desnuelle C; Laforêt P
    Arch Phys Med Rehabil; 2009 Jul; 90(7):1094-101. PubMed ID: 19577021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study.
    Mercuri E; Messina S; Battini R; Berardinelli A; Boffi P; Bono R; Bruno C; Carboni N; Cini C; Colitto F; D'Amico A; Minetti C; Mirabella M; Mongini T; Morandi L; Dlamini N; Orcesi S; Pelliccioni M; Pane M; Pini A; Swan AV; Villanova M; Vita G; Main M; Muntoni F; Bertini E
    Neuromuscul Disord; 2006 Feb; 16(2):93-8. PubMed ID: 16427782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.